Skip to main content

Advertisement

SpringerLink
Log in

131I-Induced Graves’ disease in patients treated for toxic multinodular goitre: systematic review and descriptive analysis

  • Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background

Graves’ disease (GD) arising after the treatment of toxic multinodular goitre (TMNG) with radioiodine has long been described but it remained unclear whether GD was in fact iodine induced, its incidence, risk factors, natural history and treatment outcomes. Methods: A systematic search using The Cochrane Library, Medline and PubMed Central allowed the pooling of data from 3633 patients with thyroid autonomy, 1340 patients with TMNG, to fill gaps in knowledge, regarding the clinical expression of iodine-induced GD (131I-IGD) in adults.

Results

131I-IGD developed in 0–5.3% of those with thyroid autonomy (first year) and in 5–5.4% of those with TMNG, 3–6 months after treatment. Patients with toxic adenoma were less affected. 131I-IGD was more common in patients with pre-treatment direct or indirect signs of autoimmunity: positive anti-TPO (p < 0.05), glandular hypoechogenicity, TRAbs within reference range, diffuse uptake on 99mTc-pertechnetate scans (p < 0.05), findings that may increase the risk tenfold. 131I-IGD manifested 3 months after 131I, justifying 15.4–29% of cases of relapse. The rate of spontaneous remission was 17–20% (6 months) and the rate of relapse after a second 131I treatment 22–25%. The use of an uptake-based administered 131I activity led to a greater proportion of euthyroid patients (78% compared to 25–50% with the mass-based approach).

Conclusions

GD may be triggered by 131I. The incidence of the condition is low. Several risk factors were consistently identified; some have shown to raise the risk significantly. 131I-IGD seems more treatment resistant than iodine-independent GD and the best resolution rates were achieved with uptake-based selected iodine activities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hertz B, Schuller K, Hertz S (2010) A Pioneer in the Use of Radioactive Iodine. Endocr Pract 16(4):713–715

    Article  PubMed  Google Scholar 

  2. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA (2016) American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10):1343–1421

    Article  PubMed  Google Scholar 

  3. Bonnema SJ, Hegedüs L (2012) Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 33(6):920–980

    Article  PubMed  CAS  Google Scholar 

  4. Davies TF, Ando T, Lin R, Tomer Y, Latif R (2005) Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest 115(8):1972–1983

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. DeGroot LJ (1997) Radioiodine and immune system. Thyroid 7:259–264

    Article  PubMed  CAS  Google Scholar 

  6. McGregor AM, McLachlan SM, Smith BR, Hall R (1979) Effect of irradiation on thyroid-autoantibody production. Lancet 2(8140):442–444

    Article  PubMed  CAS  Google Scholar 

  7. Kay T, Heyma P, Harrison L, Martin FIR (1987) Graves’ disease induced by radioactive iodine. Ann Intern Med 107:857–858

    Article  PubMed  CAS  Google Scholar 

  8. Weetman AP (1992) Autoimmune thyroiditis: predisposition and pathogenesis. Clin Endocrinol 36:307–323

    Article  CAS  Google Scholar 

  9. Nygaard B, Faber J, Veje A, Hegedus L, Hansen JM (1999) Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid 9:477–481

    Article  PubMed  CAS  Google Scholar 

  10. Custro N, Ganci A, Scafidi V (2003) Relapses of hyperthyroidism in patients treated with radioiodine for nodular goiter: relation to thyroid autoimmunity. J Endocrinol Invest 26(2):106–110

    Article  PubMed  CAS  Google Scholar 

  11. Syed AA, Evans C, Ludgate M, Lazarus JH (2003) Early changes in thyroid-stimulating antibody activity following radioiodine therapy. Med Princ Pract 12(4):266–268

    Article  PubMed  Google Scholar 

  12. Dunkelmann S, Wolf R, Koch A, Kittner C, Groth P, Schuemichen C (2004) Incidence of radiation-induced Graves’ disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J Nucl Med Mol Imaging 31:1428–1434

    Article  PubMed  Google Scholar 

  13. Meller J, Siefker U, Hamann A, Hüfner M (2006) Incidence of radioiodine induced Graves’ disease in patients with multinodular toxic goiter. Exp Clin Endocrinol Diabetes 114(5):235–239

    Article  PubMed  CAS  Google Scholar 

  14. Schmidt M, Gorbauch E, Dietlein M, Faust M, Stützer H, Eschner W, Theissen P, Schicha H (2006) Incidence of postradioiodine immunogenic hyperthyroidism/Graves’ disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid 16:281–288

    Article  PubMed  CAS  Google Scholar 

  15. Hovens GC, Heemstra KA, Buiting AM, Stokkel MP, Karperien M, Ballieux BE, Pereira AM, Romijn JA, Smit JW (2007) Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves’ disease measured with a novel bioassay. Nucl Med Commun 28(2):123–127

    Article  PubMed  CAS  Google Scholar 

  16. Nygaard B, Knudsen JH, Hegedüs L, Veje A, Hansen JEM (1997) Thyrotropin receptor antibodies and Graves’ disease, a side effect of 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab 82:2926–2930

    PubMed  CAS  Google Scholar 

  17. Chiovato L, Santini F, Vitti P, Bendinelli G, Pinchera A (1994) Appearance of thyroid stimulating antibody and Graves’ disease after radioiodine therapy for toxic nodular goitre. J Clin Endocrinol 40:803–806

    Article  CAS  Google Scholar 

  18. Soule J, Mayfield R (2001) Graves’ disease after 131I therapy for toxic nodule. Thyroid 10:91–92

    Article  Google Scholar 

  19. Smyth PPA, Neylan D, McMullan NM, Smith DF, McKenna TJ (1988) Sequential presentation of a case of hyperthyroidism with autonomously functioning nodules and Graves’ disease in the presence of IgG thyroid stimulators. Acta Endocrinol (Copenh) 118:474–478

    Article  CAS  Google Scholar 

  20. Regalbuto C, Salamone S, Scollo C, Vigneri R, Pezzino V (1999) Appearance of anti TSH-receptor antibodies and clinical Graves’ disease after radioiodine therapy for hyperfunctioning thyroid adenoma. J Endocrinol Invest 22(2):147–150

    Article  PubMed  CAS  Google Scholar 

  21. Nygaard B, Faber J, Veje A, Hegedus L, Hansen JM (1995) Appearance of Graves’- like disease after radioiodine therapy for toxic as well as non-toxic multinodular goitre. Clin Endocrinol (Oxf) 43:129–130

    Article  CAS  Google Scholar 

  22. Nygaard B, Metcalfe RA, Phipps J, Weetman AP, Hegedus L (1999) Graves’ disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter. J Endocrinol Invest 22:481–485

    Article  PubMed  CAS  Google Scholar 

  23. Yürekli Y, Cengiz A, Güney E (2015) Graves’ disease induced by radioiodine therapy for toxic nodular goiter: a case report. Mol Imaging Radionucl Ther 24:135–137

    Article  PubMed  PubMed Central  Google Scholar 

  24. Niepomniszcze H, Pitoia F, Goodall C, Manavela M, Bruno OD (2001) Development of Graves’ hyperthyroidism after radioiodine treatment for a toxic nodule: is the hyperthyroidism always triggered by 131I therapy? Thyroid 11(10):991

    Article  PubMed  CAS  Google Scholar 

  25. Huysmans AK, Hermus RM, Edelbroek MA, Tjabbes T, Oostdijk A, Ross HA, Corstens FH, Kloppenborg PW (1997) Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters. Thyroid 7(4):535–539

    Article  PubMed  CAS  Google Scholar 

  26. Van Leussen JJ, Edelbroek MA, Talsma MA, De Heide LJ (2000) Graves’ disease induced by Na(131)I therapy for toxic multinodular goiter. Neth J Med 57(5):194–197

    Article  PubMed  Google Scholar 

  27. Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, Pinchera A (1998) Outcome of thyroid function in Graves’ patients treated with radioiodine: role of thyroid stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 83(1):40–46

    PubMed  CAS  Google Scholar 

  28. Michelangeli VP, Poon C, Topliss DJ, Colman PG (1995) Specific effects of radioiodine treatment on TSAb and TBAb levels in patients with Graves’ disease. Thyroid 5(3):171–176

    Article  PubMed  CAS  Google Scholar 

  29. Andrade VA, Gross JL, Maia A (2004) Serum thyrotropin-receptor autoantibodies levels after 131I therapy in Graves’ patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study. Eur J Endocrinol 151(4):467–474

    Article  PubMed  CAS  Google Scholar 

  30. Wallaschofski H, Orda C, Georgi P, Paschke R (2001) Distinction between autoimmune and non-autoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multinodular goiter. Horm Metab Res 33(8):504–507

    Article  PubMed  CAS  Google Scholar 

  31. Meller J, Jauho A, Hüfner M, Gratz S, Becker W (2000) Disseminated thyroid autonomy or Graves’ disease: reevaluation by a second generation TSH receptor antibody assay. Thyroid 10(12):1073–1079

    Article  PubMed  CAS  Google Scholar 

  32. Wallaschofski H, Muller D, Georgi P, Paschke R (2002) Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment. Horm Metab Res 34(1):36–39

    Article  PubMed  CAS  Google Scholar 

  33. Nygaard B, Hegedues L, Gervil M, Hansen JEM (1995) Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves’ disease. J Intern Med 238(6):491–497

    Article  PubMed  CAS  Google Scholar 

  34. Pedersen OM, Bennedbaek FN, Hoir-Madsen M, Jacobsen BB, Hegedus L (2000) The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid 10(3):251–259

    Article  PubMed  CAS  Google Scholar 

  35. Marcocci C, Vitti P, Cetani F, Catalano F, Conceti R, Pinchera A (1991) Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism. J Clin Endocrinol Metab 72(1):209–213

    Article  PubMed  CAS  Google Scholar 

  36. Chandramouly B, Mann D, Cunningham RP, Giegerich E (1992) Marine-Lenhart syndrome: graves’ disease with poorly functioning nodules. Clin Nucl Med 17(11):905–906

    Article  PubMed  CAS  Google Scholar 

  37. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Müller-Brand J, Müller B (2007) Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 10:334–514

    Google Scholar 

  38. Fenzi G, Hashizume K, Roudebush CP, DeGroot LJ (1979) Changes in thyroid-stimulating immunoglobulins during antithyroid therapy. J Clin Endocrinol Metab 48(4):572–576

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology, Diabetes and Metabolism Unit, Department of Internal Medicine, Hospital of Egas Moniz, Lisbon’s Occidental Center of Hospitals, Estrada do Forte do Alto do Duque, 1449-005, Lisbon, Portugal

    C. Roque & C. A. Vasconcelos

Authors
  1. C. Roque
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. A. Vasconcelos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Roque.

Ethics declarations

Conflict of interest

The authors declare not to have any conflicts of interest to disclose nor to have benefit from any sponsorship or funding.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

For this type of article formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roque, C., Vasconcelos, C.A. 131I-Induced Graves’ disease in patients treated for toxic multinodular goitre: systematic review and descriptive analysis. J Endocrinol Invest 41, 1019–1028 (2018). https://doi.org/10.1007/s40618-018-0827-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-018-0827-y

Keywords

Search

Navigation